X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
The collaboration aims to evaluate the ability of RLS-0071, a novel 15 amino acid peptide dual-targeting anti-inflammatory inhibitor of complement and neutrophil effectors, to mitigate the gastrointestinal effects of ARS (GI-ARS) in a preclinical mouse model.
Lead Product(s): RLS-0071
Therapeutic Area: Trauma (Emergency, Injury, Surgery) Product Name: RLS-0071
Highest Development Status: PreclinicalProduct Type: Peptide
Partner/Sponsor/Collaborator: National Institute of Allergy and Infectious Diseases
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Collaboration March 28, 2024
Details:
RLS-007 is a dual-targeting peptide that uniquely inhibits both complement and neutrophil-associated inflammation. It is being evaluated for the treatment of acute exacerbations of chronic obstructive pulmonary disease.
Lead Product(s): RLS-0071
Therapeutic Area: Pulmonary/Respiratory Diseases Product Name: RLS-0071
Highest Development Status: Phase IIProduct Type: Peptide
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable February 21, 2024
Details:
RLS-0071 is the Company’s lead dual-action complement and innate inflammatory inhibitor peptide in development for acute exacerbations of chronic obstructive pulmonary disease, and other rare and acute inflammatory diseases.
Lead Product(s): RLS-0071
Therapeutic Area: Immunology Product Name: RLS-0071
Highest Development Status: IND EnablingProduct Type: Peptide
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 24, 2023
Details:
RLS-0071 is the Company’s lead dual-action complement and innate inflammatory inhibitor peptide in development for aGvHD, hypoxic-ischemic encephalopathy (HIE), and other rare and acute inflammatory diseases.
Lead Product(s): RLS-0071
Therapeutic Area: Immunology Product Name: RLS-0071
Highest Development Status: IND EnablingProduct Type: Peptide
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 06, 2023
Details:
RLS-0071, an investigational new drug, is the Company’s lead dual action complement inhibitor and innate anti-inflammatory peptide in development for the treatment of Hypoxia-Ischemia, Brain, acute GvHD and acute COPD.
Lead Product(s): RLS-0071
Therapeutic Area: Neurology Product Name: RLS-0071
Highest Development Status: Phase IIProduct Type: Peptide
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable August 01, 2023
Details:
RLS-0071 is ReAlta’s lead dual-action complement inhibitor and innate anti-inflammatory peptide in development as a treatment for hypoxic ischemic encephalopathy, severe asthma, and other rare diseases.
Lead Product(s): RLS-0071
Therapeutic Area: Neurology Product Name: RLS-0071
Highest Development Status: Phase IProduct Type: Peptide
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 23, 2022
Details:
RLS-0071 is the Company’s lead dual action complement inhibitor and innate anti-inflammatory peptide in development as a treatment for hypoxic-ischemic encephalopathy and other rare diseases.
Lead Product(s): RLS-0071
Therapeutic Area: Neurology Product Name: RLS-0071
Highest Development Status: Phase IIProduct Type: Peptide
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 30, 2022
Details:
ReAlta Life Sciences' double-blind, placebo-controlled Phase 1b clinical trial evaluating RLS-0071 for the treatment of ALI due to COVID-19 pneumonia in early respiratory failure will be conducted at multiple participating clinical sites throughout North America and Europe.
Lead Product(s): RLS-0071
Therapeutic Area: Pulmonary/Respiratory Diseases Product Name: RLS-0071
Highest Development Status: Phase IProduct Type: Peptide
Partner/Sponsor/Collaborator: The Virginia Catalyst
Deal Size: $3.2 million Upfront Cash: Undisclosed
Deal Type: Funding June 08, 2021
Details:
Prior to the amendment, the Phase 1 trial was a single ascending dose randomized, double-blind, placebo-controlled, adaptive-design study to evaluate the safety, tolerability, PK and PD of RLS-0071 in healthy subjects.
Lead Product(s): RLS-0071
Therapeutic Area: Pulmonary/Respiratory Diseases Product Name: RLS-0071
Highest Development Status: Phase IProduct Type: Peptide
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable May 18, 2021
Details:
RLS-0071 is a dual targeting anti-inflammatory peptide that inhibits complement and inflammatory processes such as neutrophil activation and NETosis.
Lead Product(s): RLS-0071
Therapeutic Area: Trauma (Emergency, Injury, Surgery) Product Name: RLS-0071
Highest Development Status: Phase IProduct Type: Peptide
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable February 16, 2021
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
